About: How is immunosuppressive status affecting children and adults in SARS-CoV-2 infection? A systematic review

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: How is immunosuppressive status affecting children and adults in SARS-CoV-2 infection? A systematic review Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	How is immunosuppressive status affecting children and adults in SARS-CoV-2 infection? A systematic review
Creator	Giaquinto, Carlo Barbieri, Elisa Donà, Daniele Minotti, Chiara Tirelli, Francesca Pharmd, Elisa
Source	Elsevier; Medline; PMC
abstract	Abstract Objectives SARS-CoV-2 infection has now a global resonance. Data on how COVID-19 is affecting immunocompromised patients are however few. With our study we aimed to systematically review the current knowledge on SARS-CoV-2 cases in children and adults with immunosuppression, to evaluate outcomes in this special population. Methods A systematic review of literature was carried out to identify relevant articles, searching the EMBASE, Medline, and Google Scholar databases. Studies reporting data on pre-defined outcomes and related to immunosuppressed adults and children with SARS-CoV-2 were included. Results Sixteen relevant articles were identified with 110 immunosuppressed patients, mostly presenting cancer, along with transplantation and immunodeficiency. Cancer was more often associated with a more severe course, but not necessarily with a bad prognosis. Our data show that both children and adults with immunosuppression seem to have a favorable disease course, as compared to the general population. Conclusion Immunosuppressed patients with COVID-19 seem to be few in relation to the overall figures, and to present a favorable outcome as compared to other comorbidities. This might be explained by a hypothetical protective role of a weaker immune response, determining a milder disease presentation and thus underdiagnosis. Nevertheless, surveillance on this special population should be encouraged.
has issue date	2020-04-23(xsd:dateTime)
bibo:doi	10.1016/j.jinf.2020.04.026
bibo:pmid	32335173
has license	els-covid
sha1sum (hex)	e5b2b16606248c9c9640dda13d0c0b1dfe56e37b
schema:url	https://doi.org/10.1016/j.jinf.2020.04.026
resource representing a document's title	How is immunosuppressive status affecting children and adults in SARS-CoV-2 infection? A systematic review
has PubMed Central identifier	PMC7179496
has PubMed identifier	32335173
schema:publication	J Infect
resource representing a document's body	covid:e5b2b16606248c9c9640dda13d0c0b1dfe56e37b#body_text
is schema:about of	named entity 'Objectives' named entity 'review' named entity 'immunosuppressive' named entity 'SARS-CoV-2' named entity 'immunocompromised' named entity 'immunosuppression' named entity 'COVID' named entity 'infection' named entity 'immunocompromised patients' named entity 'infection' named entity 'immunosuppressive' named entity 'immunodeficiency' named entity 'host response' named entity 'immunosuppressive therapy' named entity 'malignancies' named entity 'infectious process' named entity 'lock-down' named entity 'hypertension' named entity 'elderly age' named entity 'COVID' named entity 'oncologic' named entity 'ICU' named entity 'immunosuppressed' named entity 'ICU' named entity 'infection' named entity 'comorbidities' named entity 'SARS-CoV' named entity 'psychological disorders' named entity 'Comorbidities' named entity 'immune response' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'malignancy' named entity 'diabetes' named entity 'SpO2' named entity 'invasive ventilation' named entity 'lobectomies' named entity 'pulmonary infection' named entity 'Coronaviruses' named entity 'viral shedding' named entity 'influenza infection' named entity 'COVID' named entity 'life stages' named entity 'diabetes' named entity 'immunosuppressed' named entity 'China' named entity 'diabetes' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'CT scan' named entity 'ICU' named entity 'long-term' named entity 'transplant recipients' named entity 'hypertension' named entity 'probability' named entity 'infection' named entity 'pre-existing conditions' named entity 'diabetes' named entity 'immune response' named entity 'cardiovascular disease' named entity 'young children' named entity 'chemotherapy' named entity 'intensive care' named entity 'anti-tumor' named entity 'hyaline' named entity 'sample size' named entity 'immunosuppressed' named entity 'general population' named entity 'immune tolerance' named entity 'lungs' named entity 'Hubei Province, China' named entity 'immune tolerance' named entity 'oxygen' named entity 'comorbidity' named entity 'immunosuppressed' named entity 'comorbidity'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software